Intellia falls as FDA places clinical hold on its gene therapy trials

INTELLIA THERAPEUTICS

30/10/2025 09:01

** Shares of gene therapy developer Intellia Therapeutics NTLA.O fall 14.2% to $11.23 premarket

** Late on Wednesday, the U.S. FDA placed a clinical hold on Intellia's two late-stage trials testing experimental gene therapy nexiguran ziclumeran (nex-z)

** The therapy was being tested for transthyretin amyloidosis, a rare and progressive disease that can damage the heart and nerves

** The FDA's decision follows a serious safety event where a patient who received the therapy developed signs of potential liver damage

** Up to last close, stock up 12.5% YTD

 (Reporting by Christy Santhosh)

 ((Christy.Santhosh@thomsonreuters.com))